Latest Pharmaceuticals And Biotechnology News

Page 1 of 2
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.
Victor Sage
Victor Sage
16 Oct 2026
Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.
Victor Sage
Victor Sage
30 Sept 2026
Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.
Ada Torres
Ada Torres
3 July 2026
Cann Group Limited has agreed to fully redeem its outstanding convertible notes with Obsidian Global GP, LLC at 100% of face value, foregoing the usual early redemption premium. This move concludes the convertible securities facility established earlier in the year.
Ada Torres
Ada Torres
30 June 2026
Xenitra Limited has secured $1.25 million through a share placement to accelerate its OTC medicines rollout and expand its OPAL RWA token ecosystem, with shareholder approval pending for attached options.
Ada Torres
Ada Torres
7 May 2026
Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.
Ada Torres
Ada Torres
28 Jan 2026
Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.
Ada Torres
Ada Torres
28 Jan 2026
Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.
Ada Torres
Ada Torres
15 Dec 2025
Cann Group Limited has successfully raised an additional $2.5 million through a Share Purchase Plan and shortfall placement, complementing a prior $6.5 million institutional placement. These funds will primarily support debt repayment and strengthen the company’s financial position.
Ada Torres
Ada Torres
20 Nov 2025
Cann Group Limited has finalized a $15.3 million settlement with National Australia Bank, releasing all security and closing loan facilities as part of a broader debt restructuring. The company is advancing a $9 million new loan and a $9 million capital raise, including a share purchase plan closing November 17.
Ada Torres
Ada Torres
11 Nov 2025
Cann Group Limited has executed a transformative debt restructure, reducing its $70 million debt by 81% and raising $9 million in fresh capital, setting the stage for a positive EBITDA turnaround in FY26.
Ada Torres
Ada Torres
27 Oct 2025

Browse the archive

Full archive